Rfus-949
Phase 1
Rfus-949 is one of 50 therapeutic programs targeting Chronic pain. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
77 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Marinol
Jazz PharmaceuticalsApproved
Intuniv
PPromius Pharma, LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Tylenol
KKenvue Brands
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Bendopa
MMerz North America, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic pain1 trial
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of RFUS-949 Tablets in Healthy Chinese Participants
Active, not recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT07676357·28 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Rfus-949. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]